MannKind Stock Forecast, Price & News

+0.02 (+0.50 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.72 million shs
Average Volume3.58 million shs
Market Capitalization$1.01 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive MNKD News and Ratings via Email

Sign-up to receive the latest news and ratings for MannKind and its competitors with MarketBeat's FREE daily newsletter.

MannKind logo

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of Treprostinil (Tyvaso DPI) used for the treatment of pulmonary arterial hypertension. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

1.41 out of 5 stars

Medical Sector

712th out of 2,099 stocks

Pharmaceutical Preparations Industry

345th out of 831 stocks

Analyst Opinion: 3.4Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

MannKind (NASDAQ:MNKD) Frequently Asked Questions

Is MannKind a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MannKind stock.
View analyst ratings for MannKind
or view top-rated stocks.

What stocks does MarketBeat like better than MannKind?

Wall Street analysts have given MannKind a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but MannKind wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is MannKind's next earnings date?

MannKind is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for MannKind

How were MannKind's earnings last quarter?

MannKind Co. (NASDAQ:MNKD) announced its quarterly earnings data on Wednesday, May, 12th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by $0.01.
View MannKind's earnings history

How has MannKind's stock been impacted by Coronavirus?

MannKind's stock was trading at $1.10 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MNKD stock has increased by 268.2% and is now trading at $4.05.
View which stocks have been most impacted by COVID-19

What price target have analysts set for MNKD?

5 Wall Street analysts have issued 1-year target prices for MannKind's stock. Their forecasts range from $5.00 to $8.00. On average, they anticipate MannKind's share price to reach $6.30 in the next twelve months. This suggests a possible upside of 55.6% from the stock's current price.
View analysts' price targets for MannKind
or view top-rated stocks among Wall Street analysts.

Who are MannKind's key executives?

MannKind's management team includes the following people:
  • Dr. Michael E. Castagna, CEO & Director (Age 44, Pay $983k) (LinkedIn Profile)
  • Mr. Steven B. Binder, Chief Financial Officer (Age 58, Pay $674.71k) (LinkedIn Profile)
  • Mr. Joseph Kocinsky, Chief Technology Officer (Age 57, Pay $642.92k)
  • Dr. David B. Thomson, Exec. VP, Gen. Counsel & Sec. (Age 54, Pay $728.74k)
  • Dr. Stuart A. Tross, Chief People & Workplace Officer (Age 54, Pay $638.38k) (LinkedIn Profile)
  • Ms. Rosabel Realica Alinaya, VP of Investor Relations & Treasury (Age 60) (LinkedIn Profile)
  • Mr. John F. Bedard, Sr. VP of Worldwide Regulatory Affairs (Age 71)
  • Mr. James Patrick McCauley Jr., J.D., M.B.A., Chief Commercial Officer (Age 55) (LinkedIn Profile)
  • Mr. Alejandro Galindo M.B.A., M.S., Chief Commercial Officer (Age 49)

Who are some of MannKind's key competitors?

What other stocks do shareholders of MannKind own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BHC), Novavax (NVAX), Geron (GERN), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD), Chesapeake Energy (CHKAQ), Micron Technology (MU), NVIDIA (NVDA), Intel (INTC) and Gilead Sciences (GILD).

What is MannKind's stock symbol?

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

Who are MannKind's major shareholders?

MannKind's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (7.53%), Geode Capital Management LLC (1.54%), Millennium Management LLC (1.16%), Northern Trust Corp (0.97%), Eversept Partners LP (0.87%) and Nuveen Asset Management LLC (0.79%). Company insiders that own MannKind stock include Alejandro Galindo, Michael Castagna, Patrick Mccauley, Roxanne S Austin, Steven B Binder and Stuart A Tross.
View institutional ownership trends for MannKind

Which institutional investors are selling MannKind stock?

MNKD stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, EAM Global Investors LLC, EAM Investors LLC, Credit Suisse AG, Northern Trust Corp, Squarepoint Ops LLC, Alliancebernstein L.P., and Cambridge Investment Research Advisors Inc..
View insider buying and selling activity for MannKind
or view top insider-selling stocks.

Which institutional investors are buying MannKind stock?

MNKD stock was purchased by a variety of institutional investors in the last quarter, including Eversept Partners LP, Schonfeld Strategic Advisors LLC, Citigroup Inc., Millennium Management LLC, BlackRock Inc., Rafferty Asset Management LLC, Nuveen Asset Management LLC, and Geode Capital Management LLC. Company insiders that have bought MannKind stock in the last two years include Alejandro Galindo, Michael Castagna, Patrick Mccauley, Roxanne S Austin, Steven B Binder, and Stuart A Tross.
View insider buying and selling activity for MannKind
or or view top insider-buying stocks.

How do I buy shares of MannKind?

Shares of MNKD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MannKind's stock price today?

One share of MNKD stock can currently be purchased for approximately $4.05.

How much money does MannKind make?

MannKind has a market capitalization of $1.01 billion and generates $65.14 million in revenue each year. The biopharmaceutical company earns $-57,240,000.00 in net income (profit) each year or ($0.20) on an earnings per share basis.

How many employees does MannKind have?

MannKind employs 240 workers across the globe.

When was MannKind founded?

MannKind was founded in 1991.

What is MannKind's official website?

The official website for MannKind is

Where are MannKind's headquarters?

MannKind is headquartered at 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362.

How can I contact MannKind?

MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. The biopharmaceutical company can be reached via phone at 818-661-5000 or via email at [email protected]

This page was last updated on 6/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.